ISSN: 1859 - 2872
Kết quả phẫu thuật ung thư tuyến giáp thể biệt hóa tái phát sau phẫu thuật có kháng 131I
Main Article Content
Keywords
Ung thư tuyến giáp biệt hóa, ung thư tuyến giáp biệt hóa kháng 131I, phẫu thuật ung thư tuyến giáp tái phát
Tóm tắt
Mục tiêu: Đánh giá hiệu quả phẫu thuật ung thư tuyến giáp (UTTG) thể biệt hóa tái phát kháng 131I. Đối tượng và phương pháp: Nghiên cứu tiến cứu trên 98 bệnh nhân UTTG thể biệt hóa tái phát kháng 131I đã được phẫu thuật tại Bệnh viện Trung ương Quân đội 108 từ tháng 12 năm 2018 đến tháng 11 năm 2021. Kết quả: Trong số 98 bệnh nhân UTTG biệt hóa (86 nữ, 12 nam) trong nghiên cứu này, 76,5% bệnh nhân ở giai đoạn I, theo AJCC 8th. Số lần điều trị 131I trung bình và liều tích lũy 131I trung bình là lần lượt là 2,7 lần và 351,5mCi. Phẫu thuật được thực hiện ở 6 bệnh nhân (6,1%) tái phát tại giường tuyến giáp, và 95 (96,9%) bệnh nhân được vét hạch tái phát. Biến chứng phẫu thuật xảy ra ở 10 bệnh nhân (10,2%). 28 (28,6%) bệnh nhân có đáp ứng hoàn toàn, 20 (20,4%) bệnh nhân có đáp ứng trung gian, 42 (42,9%) bệnh nhân có đáp ứng không hoàn toàn sinh hóa và 8 (8,2%) có đáp ứng không hoàn toàn về mặt cấu trúc theo tiêu chuẩn ATA 2015. Kết luận: Phẫu thuật ung thư tuyến giáp thể biệt hóa tái phát kháng 131I là phẫu thuật an toàn và hiệu quả.
Article Details
Các tài liệu tham khảo
1. Haugen BR, Alexander EK, Bible KC et al (2016) 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 26(1): 1-133.
2. Haddad RI, Nasr C, Bischoff L et al (2018) NCCN Guidelines Insights: Thyroid Carcinoma, Version 2.2018. J Natl Compr Canc Netw 16(12): 1429-1440.
3. Tuttle M ML, Haugen B, Shah J et al (2017) Thyroid‐Differentiated and Anaplastic Carcinoma - AJCC Cancer Staging Manual. 8th ed. New York City: Springer International Publishing.
4. Robbins KT, Shaha AR, Medina JE et al (2008) Consensus statement on the classification and terminology of neck dissection. Arch Otolaryngol Head Neck Surg 134(5): 536-538.
5. Tuttle RM, Haugen B, Perrier ND (2017) Updated American Joint Committee on Cancer/Tumor-Node-Metastasis Staging System for Differentiated and Anaplastic Thyroid Cancer (Eighth Edition): What Changed and Why? Thyroid 27(6): 751-756.
6. Onuma AE, Beal EW, Nabhan F et al (2019) Long-term efficacy of lymph node reoperation for persistent papillary thyroid cancer: 13-year follow-up. Ann Surg Oncol 26(6): 1737-1743.
7. Son MH, Bieu BQ, Ha LN (2016) Value of Dedicated Head and Neck (18)F-FDG PET/CT Protocol in Detecting Recurrent and Metastatic Lesions in Post-surgical Differentiated Thyroid Carcinoma Patients with High Serum Thyroglobulin Level and Negative (131)I Whole-body Scan. Asia Ocean J Nucl Med Biol 4(1): 12-18.
8. Lamartina L, Borget I, Mirghani H et al (2017) Surgery for neck recurrence of differentiated thyroid cancer: Outcomes and risk factors. J Clin Endocrinol Metab 102(3): 1020-1031.
9. Dong W, Horiuchi K, Tokumitsu H, Sakamoto, et al (2019) Time-varying pattern of mortality and recurrence from papillary thyroid cancer: Lessons from a long-term follow-up. Thyroid 29(6): 802-808.
10. Brose MS, Nutting CM, Jarzab B et al (2014) Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: A randomised, double-blind, phase 3 trial. Lancet 384(9940): 319-328.
11. Shobab L, Gomes-Lima C, Zeymo A et al (2019) Clinical, pathological, and molecular profiling of radioactive iodine refractory differentiated thyroid cancer. Thyroid 29(9): 1262-1268.
12. Wierzbicka M, Gurgul E, Wasniewska-Okupniak E, et al (2014) The feasibility and efficacy of secondary neck dissections in thyroid cancer metastases. Eur Arch Otorhinolaryngol 271(4): 795-799.
13. Lee HS, Roh JL, Gong G et al (2015) Risk factors for re-recurrence after first reoperative surgery for locoregional recurrent/persistent papillary thyroid carcinoma. World J Surg 39(8): 1943-1950.
14. Rivera-Robledo CG, Velázquez-Fernández D, Pantoja JP et al (2019) Recurrent papillary thyroid carcinoma to the cervical lymph nodes: Outcomes of compartment-oriented lymph node resection. World J Surg 43(11): 2842-2849.
15. Kalaitzidou S, Papadakis G, Sapera A et al (2020) Outcomes of surgery and radioiodine treatment for neck recurrence in papillary thyroid cancer. J buon 25(1): 383-388.
16. Lamartina L, Borget I, Mirghani H et al (2017) Surgery for neck recurrence of differentiated thyroid cancer: Outcomes and risk factors. The Journal of Clinical Endocrinology & Metabolism 102(3): 1020-1031.
17. Onuma AE, Beal EW, Nabhan F et al (2019) Long-term efficacy of lymph node reoperation for persistent papillary thyroid cancer: 13-year follow-up. Annals of surgical oncology 26(6): 1737-1743.
18. Chiapponi C, Alakus H, Faust M et al (2021) Salvage surgery for cervical radioiodine refractory 18F-FDG-PET positive recurrence of papillary thyroid cancer. Endocr Connect 10(9): 1180-1188.
2. Haddad RI, Nasr C, Bischoff L et al (2018) NCCN Guidelines Insights: Thyroid Carcinoma, Version 2.2018. J Natl Compr Canc Netw 16(12): 1429-1440.
3. Tuttle M ML, Haugen B, Shah J et al (2017) Thyroid‐Differentiated and Anaplastic Carcinoma - AJCC Cancer Staging Manual. 8th ed. New York City: Springer International Publishing.
4. Robbins KT, Shaha AR, Medina JE et al (2008) Consensus statement on the classification and terminology of neck dissection. Arch Otolaryngol Head Neck Surg 134(5): 536-538.
5. Tuttle RM, Haugen B, Perrier ND (2017) Updated American Joint Committee on Cancer/Tumor-Node-Metastasis Staging System for Differentiated and Anaplastic Thyroid Cancer (Eighth Edition): What Changed and Why? Thyroid 27(6): 751-756.
6. Onuma AE, Beal EW, Nabhan F et al (2019) Long-term efficacy of lymph node reoperation for persistent papillary thyroid cancer: 13-year follow-up. Ann Surg Oncol 26(6): 1737-1743.
7. Son MH, Bieu BQ, Ha LN (2016) Value of Dedicated Head and Neck (18)F-FDG PET/CT Protocol in Detecting Recurrent and Metastatic Lesions in Post-surgical Differentiated Thyroid Carcinoma Patients with High Serum Thyroglobulin Level and Negative (131)I Whole-body Scan. Asia Ocean J Nucl Med Biol 4(1): 12-18.
8. Lamartina L, Borget I, Mirghani H et al (2017) Surgery for neck recurrence of differentiated thyroid cancer: Outcomes and risk factors. J Clin Endocrinol Metab 102(3): 1020-1031.
9. Dong W, Horiuchi K, Tokumitsu H, Sakamoto, et al (2019) Time-varying pattern of mortality and recurrence from papillary thyroid cancer: Lessons from a long-term follow-up. Thyroid 29(6): 802-808.
10. Brose MS, Nutting CM, Jarzab B et al (2014) Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: A randomised, double-blind, phase 3 trial. Lancet 384(9940): 319-328.
11. Shobab L, Gomes-Lima C, Zeymo A et al (2019) Clinical, pathological, and molecular profiling of radioactive iodine refractory differentiated thyroid cancer. Thyroid 29(9): 1262-1268.
12. Wierzbicka M, Gurgul E, Wasniewska-Okupniak E, et al (2014) The feasibility and efficacy of secondary neck dissections in thyroid cancer metastases. Eur Arch Otorhinolaryngol 271(4): 795-799.
13. Lee HS, Roh JL, Gong G et al (2015) Risk factors for re-recurrence after first reoperative surgery for locoregional recurrent/persistent papillary thyroid carcinoma. World J Surg 39(8): 1943-1950.
14. Rivera-Robledo CG, Velázquez-Fernández D, Pantoja JP et al (2019) Recurrent papillary thyroid carcinoma to the cervical lymph nodes: Outcomes of compartment-oriented lymph node resection. World J Surg 43(11): 2842-2849.
15. Kalaitzidou S, Papadakis G, Sapera A et al (2020) Outcomes of surgery and radioiodine treatment for neck recurrence in papillary thyroid cancer. J buon 25(1): 383-388.
16. Lamartina L, Borget I, Mirghani H et al (2017) Surgery for neck recurrence of differentiated thyroid cancer: Outcomes and risk factors. The Journal of Clinical Endocrinology & Metabolism 102(3): 1020-1031.
17. Onuma AE, Beal EW, Nabhan F et al (2019) Long-term efficacy of lymph node reoperation for persistent papillary thyroid cancer: 13-year follow-up. Annals of surgical oncology 26(6): 1737-1743.
18. Chiapponi C, Alakus H, Faust M et al (2021) Salvage surgery for cervical radioiodine refractory 18F-FDG-PET positive recurrence of papillary thyroid cancer. Endocr Connect 10(9): 1180-1188.
Article Sidebar
Đã đăng
Feb 28, 2023
Số tạp chí
Chuyên mục
Articles
Trích dẫn bài viết này
Dũng Đặng T., HàL. N., & KiểmT. T. (2023). Kết quả phẫu thuật ung thư tuyến giáp thể biệt hóa tái phát sau phẫu thuật có kháng 131I. Journal of 108 - Clinical Medicine and Phamarcy, 18(2). https://doi.org/10.52389/ydls.v18i2.1742